Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics (SRPT) reported Q3 2025 results. Total revenues were $399.4 million versus $467.2 million a year ago, with product revenues of $370.0 million and collaboration and other revenues of $29.3 million. ELEVIDYS U.S. product revenue was $131.5 million versus $181.0 million, and PMO product revenues were $238.5 million versus $248.8 million.
The company posted an operating loss of $103.4 million and a net loss of $179.9 million for the quarter. Year to date, total revenues reached $1.76 billion versus $1.24 billion, but the company recorded a net loss of $430.6 million driven by a $583.6 million acquired IPR&D expense from the Arrowhead deal and a $138.6 million loss on debt extinguishment tied to a 2027-to-2030 notes exchange.
Cash and cash equivalents were $613.1 million, with short‑term investments of $237.9 million. Deferred revenue current portion rose to $485.4 million. The company repurchased $25.3 million of stock under a $500 million authorization. Sarepta suspended commercial shipments of ELEVIDYS to non‑ambulatory patients in June 2025 and is in ongoing FDA discussions regarding a labeling supplement, including a boxed warning for acute liver injury and acute liver failure and removal of the non‑ambulatory population from Indication and Usage.
Sarepta Therapeutics (SRPT) reported that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company furnished the full text of the release as Exhibit 99.1 to this Form 8-K.
The company stated that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
The Vanguard Group filed Amendment No. 11 to Schedule 13G for Sarepta Therapeutics, Inc. (SRPT), reporting ownership of 10,641,733 shares, equal to 10.89% of the outstanding common stock. Vanguard reports 0 sole voting power, 606,072 shared voting power, 9,925,846 sole dispositive power, and 715,887 shared dispositive power. The filing states these shares are held in the ordinary course of business and are not intended to influence control of the issuer. The filing identifies Vanguard's Malvern, PA address and is signed by Ashley Grim, Head of Global Fund Administration, dated 09/08/2025.
Louise Rodino-Klapac, President of R&D and Tech Ops at Sarepta Therapeutics (SRPT), reported insider acquisitions on Form 4. On 09/03/2025 she was granted two awards of restricted stock units (RSUs): 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027, and 50,000 performance-based RSUs that vest 100% on 09/03/2028 subject to service and achievement of performance criteria. The transactions were reported as acquisitions at $0 per share because they are equity awards. Following the grants and an earlier purchase of 106 shares on 08/31/2025 under the ESPP, she beneficially owned 228,612 shares after the reported transactions.
Ryan Ho-Yan Wong, Chief Financial Officer of Sarepta Therapeutics (SRPT), reported grants of restricted stock units on 09/03/2025. He received 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027, and an additional 25,000 performance-based RSUs that vest 100% on 09/03/2028 only if certain performance criteria are met and he remains in service. The reported price for both grants is $0. Following the 09/03/2025 transactions, the filing shows beneficial ownership totaling 136,203 shares. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Ian Michael Estepan, Chief Operating Officer of Sarepta Therapeutics (SRPT), reported two grants of restricted stock units on 09/03/2025. He received 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027. He also received 50,000 performance-based RSUs that vest 100% on 09/03/2028 subject to service and performance committee approval. Following the grants his beneficial ownership increased to 156,487 shares and then to 206,487 shares. The Form 4 was signed by an attorney-in-fact on 09/05/2025. All RSUs are at $0 reported price because they are awards, not purchases.
Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics (SRPT), received stock awards totaling 118,875 restricted stock units (RSUs) on a transaction dated 09/03/2025. The awards consist of 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027 subject to continued service, and 25,000 performance-based RSUs that vest 100% on 09/03/2028 only if performance criteria are met and the Reporting Person remains in service. Each RSU represents the right to one share and the grants were reported with a $0 purchase price. Following these grants, the Reporting Person beneficially owned 139,985 shares.
Sarepta Therapeutics filed a Current Report on Form 8-K disclosing an indenture dated August 28, 2025 with U.S. Bank Trust Company, National Association as trustee that includes the form of a 4.875% Convertible Senior Note due 2030. The filing references the form of the note as included in Exhibit 4.1. The report is signed by Ian Estepan, President and Chief Operating Officer.
Sarepta Therapeutics filed an 8-K that references its quarterly report on Form 10-Q for the period ended June 30, 2025 and notes that forward-looking statements in the filing speak only as of the filing date. The filing includes a standard cautionary statement qualifying forward-looking language and is signed by Ian Estepan, President and Chief Operating Officer, dated August 21, 2025.
The notice functions as a routine corporate disclosure: it directs readers to the company’s subsequent SEC filings for updates and establishes the date of the forward-looking statement safe-harbor. No financial results, transactions, or new material agreements are disclosed in the provided text.
Sarepta Therapeutics announced the planned departure of Bilal Arif, its Executive Vice President and Chief Technical Operations Officer, as part of a strategic restructuring and pipeline prioritization. Mr. Arif served in the role through August 12, 2025, will remain a Special Advisor until his employment ends on September 16, 2025, and will provide consulting services through December 31, 2025. The company and Mr. Arif executed a Separation and Consulting Agreement dated August 12, 2025, under which he will receive a lump-sum severance payment of $576,700 and a consulting fee of $400 per hour. Outstanding equity awards will continue to vest while he remains employed or provides consulting services. The full agreement will be filed as an exhibit to the Company’s Quarterly Report for the quarter ended September 30, 2025.